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Abstract 
Background 
The TOBY-Xe proof of concept randomised trial found no effect of xenon combined with hypothermia after 
birth asphyxia on the lactate to N-acetyl aspartate ratio (Lac/NAA) in the thalamus and fractional anisotropy 
(FA) in white matter tracts measured within 15 days of birth. To confirm that these biomarkers are qualified 
to predict long-term outcome after neural rescue therapy we assessed surviving participants at 2-3 years of 
age.   
Methods 
Of the 92 infants in TOBY-Xe, one was omitted from the study, 69 survived and we assessed 62 
participants, 32 in the hypothermia and xenon and 30 in the hypothermia only groups. We examined the 
relation between Lac/NAA and FA and the scores of the Bayley Scales of Infant and Toddler Development 
III and calculated their predictive accuracy for moderate or severe disability or death. 
Results 
Fifteen of 62 participants (24%) developed moderate/severe disability, and 22/92 (24%) died.    
The Lac/NAA ratio (difference in medians 0.628, 95% CI -0.392 to 4.684) and FA (difference in means -
0.055, 95% CI -0.033 to -0.077) differed significantly between participants with or without moderate or 
severe disability or death and were significantly related with development scores in both groups. Adverse 
outcomes were correctly identified in 95.65% of cases by Lac/NAA and 78.79% by FA, with adequate mean 
calibration of the model.  
Interpretation 
The results confirm the qualification of the cerebral magnetic resonance biomarkers employed in the TOBY-
Xe study as predictors of outcome after neuroprotective therapy.  
Funding 
 
The Centre for the Developing Brain, King’s College London, UK.
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Introduction 
 
Xenon, a monoatomic gas that is approved for inhalational anaesthesia, showed promising neuroprotective 
effects when combined with moderate hypothermia following asphyxia in studies in animals and in a 
preliminary clinical study in adults following cardiac arrest.(1-4) These positive neuroprotective effects are 
usually attributed to inhibition of NMDA glutamate receptors and inhibition of apoptotic mechanisms.(5;6) 
 
To explore whether inhaled xenon gas combined with moderate hypothermia reduces cerebral injury in near 
term newborns after birth asphyxia, we carried out an open-label, proof of concept, randomised clinical trial, 
the TOBY-Xe study (NCT00934700), between 2012 and 2014.(7) In that study we compared the effects of 
24 hours of 30% inhaled xenon combined with 72 hours of hypothermia to 33.5oC with hypothermia alone 
on the lactate to N-acetyl aspartate (Lac/NAA) peak area ratio in the thalamus measured by proton (1H) 
magnetic resonance spectroscopy (MRS) and fractional anisotropy (FA) in white matter tracts on diffusion 
tensor magnetic resonance imaging within 15 days of birth. These magnetic resonance measures are 
mechanistically relevant and clinically prognostic of severe neurological impairment. The Lac/NAA ratio 
measured by proton spectroscopy is a bridging biomarker which detects the effect of neuroprotective 
therapy in animal studies. Tract based spatial statistics with diffusion tensor imaging allows statistically 
powerful assessment of white matter microstructure, and the separation of small groups of subjects, thus 
reducing the sample size significantly compared to using visual analysis (8-14). The TOBY-Xe study found 
no evidence of an effect of xenon combined with hypothermia on the cerebral biomarkers and on other 
outcomes assessed in the neonatal period. We concluded that the results did not support carrying out a large 
definitive clinical trial of treatment with xenon combined with hypothermia after birth asphyxia. 
 
Cerebral magnetic resonance biomarkers have not previously been used prospectively as the primary 
outcomes in randomised trials of potential neuroprotective therapies following birth asphyxia and neonatal 
encephalopathy. Therefore, to confirm that these biomarkers are qualified to predict long-term outcome after 
neural rescue therapy we followed up surviving TOBY-Xe participants and performed neurodevelopmental 
assessment at 2-3 years of age.  We hypothesized that there would be concordance between the early 
cerebral biomarkers and later neurodevelopmental outcome, and thus no differences on neurodevelopmental 
assessment between the two treatment groups. 
 
Methods 
 
The study was carried out in London, UK at Queen Charlotte and Chelsea Hospital, University College 
Hospital and the Evelina London Children’s Hospital. The UK National Research Ethics Service approved 
the study (15/SC/0201) and the study registry identifier is NCT03968861.  
 
The TOBY-Xe study was carried out from Jan 31, 2012, to Sept 30, 2014. We enrolled 92 infants: 46 infants 
randomly assigned to standard care including hypothermia to 33.5o C for 72 hours and 46 infants to 30% 
xenon for 24 hours, started immediately after randomisation in the first 12 hours after birth, combined with 
hypothermia. Infants were eligible if their gestational age was 36–43 weeks and they had at least one of the 
following: Apgar score of 5 or less 10 min after birth; continued need for resuscitation, including 
endotracheal or mask ventilation, 10 min after birth; or acidosis (defined as pH <7 or base deficit >15 
mmol/L, or both in umbilical cord blood or any blood sample) within 1 h of birth. Furthermore, eligible 
infants showed signs of moderate to severe encephalopathy, consisting of altered state of consciousness 
(reduced or absent response to stimulation), hypotonia, and abnormal primitive reflexes (weak or absent 
suck or Moro response), and had moderately or severely abnormal background activity for at least 30 min or 
seizures as shown by amplitude-integrated EEG (aEEG). We excluded infants if cooling was started after 6 
h from birth or if they were older than 12 h at randomisation. 
 
Magnetic resonance scans were carried out in TOBY-Xe participants within 15 days of birth. Details of the 
scanning procedures and the various sequences used in the TOBY-Xe study have been reported previously 
(7). All MRS and MRI studies were done with 3·0 Tesla systems (Philips Healthcare, Best, Netherlands) at 
each centre. The trial research physicist undertook rigorous standardisation and a quality-control programme 
with phantoms and repeated scanning. Comparability test objects were transported from site to site during 
the project. An adult volunteer was imaged at each site periodically to provide direct comparison data. 
Images were obtained according to a standard protocol that included diffusion tensor MRI with 32 non-
collinear directions, MRS from a single voxel on the left thalamus, and motion tolerant T1 and T2 structural 
scans. Tract based spatial statistics controlling for post menstrual age was used to assess diffusion tensor 
data for FA values. Total examination time for the study protocol was around 1 h.  
 
Parents who consented for follow-up were invited to bring their child back for a neurodevelopmental 
assessment at 2 years of age. A paediatrician, trained in performing neurodevelopmental assessments and 
unaware of treatment allocation in the TOBY-Xe study, carried out neurodevelopmental assessments in 
participants at each of the three sites (AD at the Queen Charlotte and Chelsea Hospital, AHC at the 
University College Hospital and AC at the Evelina London Children’s Hospital) using the Bayley Scales of 
Infant and Toddler Development III.(15) AC contacted the parents of 13 children that could not be examined 
by their local hospital paediatrician and, with the parents’ consent, carried out the assessment at the 
participants’ homes, with their parents present.  
 
Of the 92 newborns initially randomised, one was omitted from the original study due to incomparable 
magnetic resonance scanner parameters. Of the other 91 newborns recruited, 20 had died in the neonatal 
period and one at four months and one at seven months after birth. Two participants had left the country and 
5 parents declined follow-up assessment. Finally, developmental assessments were conducted in 62 of 69 
(90%) surviving children (Figure 1 – Patient flow). 
 
Sixty participants were assessed using the Bayley Scales of Infant and Toddler Development III and two 
participants older than 3.5 years were assessed using the Wechsler Preschool and Primary Scale of 
Intelligence, WPPSI-III.(16) Neurological assessment was by the Hammersmith Neurological Examination, 
reported as Optimality scores  (maximum score is 78).(17) Clinical signs of cerebral palsy were recorded 
and classified according to topographical distribution of the Surveillance of Cerebral Palsy in Europe 
classification. Functional classification was scored based on the Gross Motor Function Classification System 
(GMFCS)(18), while upper limb function was classified using the Manual Ability Classification System 
(MACS).(16) We also collected clinical information regarding health and wellbeing since hospital 
discharge, including data on vision, hearing, and seizures, and medications.  
 
Qualification of early cerebral biomarkers with neurodevelopmental outcomes 
We examined the relation between the Lac/NAA in the thalamus measured by 1H MRS and FA in white 
matter tracts on diffusion tensor magnetic resonance and the composite scores of the Cognitive, Language 
and Motor scales in surviving participants, and we calculated their predictive accuracy for moderate or 
severe disability or death. The grade of disability was categorised as mild disability (a Cognitive score of 70 
to 84, level 1 gross motor function [is able to walk independently but may have some gait abnormalities], or 
abnormality in one or both eyes with normal or nearly normal vision), moderate disability (a Cognitive scale 
score of 56 to 69, level 2 or 3 gross motor function [has minimal ability to perform gross motor skills or 
requires assistance with walking], or moderately reduced vision), or severe disability (a Cognitive scale 
score of 55 (the minimum score on the Bayley-III Cognitive scale), level 4 or 5 gross motor function [needs 
adaptive seating or has severely limited mobility], or no useful vision).  
 
Statistical analysis 
Stata (version 11) statistical software was used for the statistical analysis. 
 
Assessment of the relationship between early cerebral biomarkers and neurodevelopmental outcome: 
Lac/NAA values were skewed so we used the natural logarithm, where appropriate.  We performed linear 
regression to assess the relation between the Lac/NAA peak area ratio in the thalamus and FA in the 
posterior limb of the internal capsule to the cognitive, language and motor scale development scores, in the 
whole study population and by treatment subgroup. We included in the analyses the Full IQ, Verbal and 
Performance scores of the two children that were assessed by the WPPSI-III, as these scores have the same 
mean and standard deviation as those of the Bayley-III scales. We compared mean or median values of the 
biomarkers in the normal outcome/mild disability group and the group with moderate or severe disability or 
death. We analysed the receiver operating characteristic curve (ROC) and calculated the area under the 
curve (AUC), sensitivity, specificity, and likelihood ratios of the prediction by Lac/NAA and FA of 
moderate or severe disability, and repeated the analysis including deaths in the adverse outcome group. We 
assessed mean calibration of the prediction models by the Hosmer-Lemeshow test. 
 
In the TOBY-Xe study, the Lac/NAA ratios were not corrected for post menstrual age at scan, therefore, we 
tested for a relation between these measures by linear regression.  
 
Analyses of clinical data of participants: Since all continuous outcomes had non-Gaussian distributions, we 
present the median and interquartile range and the difference in medians with 95% confidence intervals 
between participants in the xenon combined with hypothermia and hypothermia only group. Wilcoxon rank-
sum test was used to test the null hypothesis. We calculated relative risks and 95% confidence intervals for 
categorical outcomes between the two groups. 
 
Results 
 
The clinical characteristics at birth of the study infants are shown in table 1, and the results of the key 
clinical outcome measures in table 2. The results of the developmental and neurological assessments were 
similar in the the xenon/hypothermia (Xe+) and hypothermia only group (Xe-) group. Twelve of 46 
participants (26.08%) from the Xe+ group and 10/46 (21.74%) from the Xe- group died (Relative risk: 1.2, 
95% confidence interval (CI) 0.577 to 2.498). Twenty of the 22 deaths occurred in the neonatal period and 
the other two deaths occurred at 4 and 7 months of age. The median (IQR) age when developmental 
assessment was completed was similar in both groups: Median (IQR) 25.10 (24.43 to 28.58) months in the 
Xe+ group, and Median (IQR) 25.00 (24.29 to 29.52) months in the Xe- group (Difference in Medians, 0.10, 
95% CI, 0.214 to 2.854)  
 
Relationship between early cerebral biomarkers and neurodevelopment: The  Lac/NAA ratio in the 
thalamus and FA in the posterior limb of the internal capsule measured within 15 days of birth were 
significantly related with the composite cognitive, language and motor developmental scores assessed at 2-3 
years of age in the whole population and in each treatment group (Figure 2, Table 3). The relation between 
the biomarkers and the developmental scale scores appeared to tail off at low values of the developmental 
scores, probably due to the fixed minimum scores applied in the Bayley III (Figure 2). However, a linear 
function described the relationship reasonably well. Using a quadratic term in the regression did not improve 
the line of best fit. Excluding the data from the two infants assessed by WPPSI-III did not materially change 
the result of the analyses.   
 
The Lac/NAA ratio and the FA values differed between the normal outcome/mild disability and 
moderate/severe disability or death groups (Figure 3 and table 4). Both measures also accurately predicted 
moderate/severe disability in the surviving participants and also when deaths were included in the adverse 
outcome group (Figure 4 and table 5). The Hosmer-Lemeshow goodness of fit test of the predictive models 
using all observations in the data indicated adequate mean calibration (P=0.144 for Log Lac/NAA, P=0.678 
for FA and P=0.483 for Lac/NAA plus FA). 
 
There was no correlation between the Lac/NAA ratios and post menstrual age at scan (P=0.272, r2 0.020, 
Figure 5) 
 
Discussion 
 
The Lac/NAA ratio in the thalamus and FA in the posterior limb of the internal capsule measured within 15 
days of birth were highly correlated with neurodevelopmental outcomes and accurately predicted the 
occurrence of moderate or severe disability in the surviving children or death in each randomised group. The 
results confirm the qualification of the cerebral magnetic resonance biomarkers employed in the TOBY-Xe 
study as predictors of outcome after neuroprotective therapy following birth asphyxia.  
 
Recent studies confirmed the accuracy of MRS and MRI biomarkers for predicting an adverse outcome 
following birth asphyxia and neonatal encephalopathy, but without testing any therapeutic 
intervention.(10;11)  The present study thus aimed to confirm prospectively the qualification of the cerebral 
biomarkers after an adjunct neuroprotective treatment with therapeutic hypothermia. Studies in animals have 
shown that the thalamic Lac/NAA ratio is a sensitive biomarker of the therapeutic and biological effects of 
hypothermia and of adjunct treatment with hypothermia following asphyxia, and we have previously shown 
the value of MR imaging as a biomarker after therapeutic hypothermia in a retrospective analysis of the 
TOBY randomised trial of therapeutic hypothermia.(19-22) In such studies, using MRS sequences at 3T 
similar to those in babies with neonatal encephalopathy, Lac/NAA is consistently associated with the 
number of dead cells on brain immunohistochemistry and with the recovery of aEEG after hypoxia 
ischaemia. Translating these pre-clinical data to the clinical TOBY-Xe study gives us confidence in 
Lac/NAA to detect a biological effect or not as is the case here with the addition of xenon to hypothermia. 
Such studies show that the Lac/NAA ratio is robust enough to clearly demonstrate a biological effect if it 
existed. The TOBY-Xe study failed to show a therapeutic effect of adjunct treatment with xenon in neonatal 
encephalopathy, and our results confirm that the cerebral biomarkers do not detect an effect that is not real. 
Our results demonstrate the high predictive accuracy of the cerebral biomarkers in both randomised groups. 
Our data, together with the data from pre-clinical and clinical observational studies show that the cerebral 
biomarkers chosen in the TOBY-Xe study are  accurate in predicting later outcomes following neural rescue 
therapy, supporting their use to assess a therapeutic effect on clinical outcomes in the two outcome groups, 
and estimate the power of the study to detect clinically significant changes in the cerebral biomarkers.  
 
The MARBLE study reported that the NAA metabolite concentration in the thalamus was the optimal 
predictor following neonatal encephalopathy, but another recent study reported a similar predictive accuracy 
for the thalamic Lac/NAA ratio.(11)  The predictive performance of the Lac/NAA ratio in our study was 
nearly identical to that reported in the MARBLE study when deaths are included in the adverse outcome 
group (AUC 0.94, 95% CI 0.89-0.97 in MARBLE and AUC 0.938, 95% CI 0.866-1.000 in this study). The 
data are thus consistent. In the MARBLE study thalamic metabolite concentrations were obtained in 43% of 
participants, and peak area thalamic metabolite ratios in 84% of infants. Our multicenter study using 
purposely developed scanning protocols and compatible scanners acquired peak area thalamic metabolite 
ratios from all 78 infants who had an MRI scan in the neonatal period and FA data from 73/78 (95%) 
infants, proving the feasibility of using these biomarkers in clinical trials.   
 
Although standard magnetic resonance imaging with visual assessment is now commonly used to assess the 
severity of cerebral injury and guide management following birth asphyxia and neonatal encephalopathy, the 
high accuracy for predicting later neuro-developmental outcome and the feasibility of measuring the 
Lac/NAA ratio on 1H MRS confirmed in this study indicate that this is potentially a clinically useful 
measure that could be incorporated into clinical practice. However, since 1H MRS studies in newborns have 
been in specialist centres, further clinical studies are needed to determine the feasibility and cost/benefits of 
introducing this measure routinely in infants with neonatal encephalopathy. 
 
Two infants, one from each allocation group, had zero Lac/NAA values on proton MRS, and both infants 
developed severe disabilities. Absence of a lactate signal following severe asphyxial encephalopathy is 
highly unusual and we cannot exclude that the infants had an alternative pathology. These two data points 
are dropped following log normal transformation as log normal transformation of zero values is not possible. 
 
Studies in animals have suggested that there are several potential neuroprotectants that might augment the 
modest therapeutic effect of moderate hypothermia following birth asphyxia. However, clinical trials of 
adjunct neuroprotective therapies initiated very soon after birth with clinical outcomes require large 
numbers, have a long duration and are costly. There is a critical need for statistically powerful qualified 
biomarkers measured soon after cerebral injury for rapid assessment of potential therapies in proof of 
concept studies. The present results confirm that cerebral magnetic resonance biomarkers, such as used in 
our study, provide a rapid and accurate surrogate outcome that can be used to identify useless interventions 
early and select promising neuroprotectants for further study. 
 
Neurological and neurodevelopmental outcomes at 2-3 years of age were very similar in the xenon plus 
hypothermia and hypothermia only groups, mirroring the closeness of the results between groups of the 
cerebral biomarkers measured soon after birth, visual analysis of conventional MRI and neurological 
assessment at hospital discharge in the neonatal period. There was no difference in deaths and loss to 
follow-up in the two randomised groups, so the randomisation property still broadly applies to the 2-3-year 
outcomes, but this study was not designed to detect an effect of xenon on neurodevelopmental outcomes and 
was underpowered to do so because TOBY-Xe was powered to detect changes in the cerebral biomarkers.  
However, the near identical results of the clinical outcomes in the two treatment groups, and the close 
concordance with the neonatal outcomes suggest a low probability that the results would materially change 
with a larger study. 
 
The results also confirm that a definitive clinical trial of xenon gas combined with moderate hypothermia 
after birth asphyxia would not be appropriate using the protocol defined in the TobyXe study. The absence 
of a beneficial effect of xenon could be for a number of reasons, such as: suboptimal dose, duration and 
timing of administration of xenon (the mean age of starting xenon in TOBY-Xe was almost 10h); the 
severity of encephalopathy in the participants; low sensitivity of the cerebral biomarkers used in the study; 
and low power of the follow-up study. Neuroprotective therapies are less likely to be successful following 
more severe injury, as was demonstrated in a recent study in animals that found no cerebral protection with 
xenon following a severe asphyxial insult whilst previous studies found beneficial effects following milder 
injury.(23) However, it is unlikely that the TobyXe study participants were more severely affected than 
infants recruited to the successful large randomised trials of cooling since the eligibility criteria of the 
TobyXe study were similar to those of the cooling trials, and the mortality and severe disability rates did not 
differ greatly from that reported in those trials.(24) 
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Legends 
 
Figure 1 Patient flow in study 
 
Figure 2: Plot of Log Lac/NAA (N=57) and FA (N=56) with cognitive, language and motor developmental 
scores 
 
Figure 3: Receiver operating characteristic curves of Lac/NAA ratio (N=69) and FA (N=66) and the 
combination of Lac/NAA and FA (N=63) for predicting moderate/severe disability/deaths at 2-3 years 
 
Figure 4: Plot of log Lac/NAA (N=69) and FA (N=66) values and outcome at 2-3 years of age by treatment 
group 
 
Footnote to Figure 4:  
Two group t test of means of Lac/NAA on the log scale, in normal outcome/mild disability and moderate/severe 
disability/deaths groups in Xe+ group, P<0.001and Xe- groups, P<0.001; Two group t test of means of FA, in 
normal outcome/mild disability and moderate/severe disability/deaths groups in Xe+, P<0.001and Xe- groups, 
P<0.001 
 
Figure 5: Plot of Log Lac/NAA and post menstrual age in days at scan (N=63) 
 
 
Table 1: Baseline clinical features 
 2-3-year outcomes available 2-3-year 
outcomes not 
available 
Xenon plus 
hypothermia 
N=32 
Hypothermia only 
N=30 
All infants 
N=62 
All infants 
N=7 
Treatment hospital, n (%): 
University College London 
St Thomas’ 
Queen Charlotte and Chelsea 
 
9 
12 
11 
  
10 
11 
9 
 
 
 
19 
23 
20 
 
 
 
3 
3 
1 
 
Birth in treatment centre, n (%): 12 (38) 10 (33) 22 (35) 1 (14) 
Male sex, n (%): 19 (59) 12 (40) 31 (50) 3 (43) 
Birth weight (grams): 
Mean [SD] 
 
3417 
 
[646] 
 
3265 
 
[492] 
 
3344 
 
[577] 
 
3119 
 
[406] 
Gestation at delivery (weeks): 
Mean [SD] 
 
39.9 
 
[1.7] 
 
39.8 
 
[1.4] 
 
39.8 
 
[1.6] 
 
40.4 
 
[0.9] 
Apgar at 10 minutes: 
Median (IQR) 
Unknown 
 
5 
4 
 
(4 to 6.5) 
 
5 
7 
 
(3 to 7) 
 
5 
11 
 
(4 to 7) 
 
4 
0 
 
(1 to 8) 
Cord/first blood pH: 
Median (IQR) 
Mean [SD] 
Unknown 
 
6.9 
7.0 
0 
 
(6.8 to 7.1) 
(0.2) 
 
 
6.9 
6.9 
1 
 
(6.8 to 7.2) 
(0.2) 
 
6.9 
7.0 
1 
 
(6.8 to 
7.1) 
(0.2) 
 
6.9 
6.9 
0 
 
(6.7 to 
7.0) 
(0.2) 
Base Excess (mmol/L): 
Median (IQR) 
Unknown 
 
-16.8 
2 
 
(-19.1 to -
13.5) 
 
-16.4 
4 
 
(-22.9 to -
11.1) 
 
-16.6 
6 
 
(-19.8 
to -
12.2) 
 
-22.1 
0 
 
(-26.5 
to -
19.7) 
Moderate or severe encephalopathy at trial 
entry n (%): 
 
32 
 
(100) 
 
30 
 
(100) 
 
62 
 
(100) 
 
7 
 
(100) 
Thompson hypoxic ischemic 
encephalopathy score at trial entry, n (%): 
0-10 
11-14 
15-22 
Median (IQR) 
 
 
5 
19 
8 
13 
 
 
(16) 
(59) 
(25) 
(11 to 14.5) 
 
 
2 
21 
7 
13 
 
 
(7) 
(70) 
(23) 
(11 to 14) 
 
 
7 
40 
15 
13 
 
 
(11) 
(65) 
(24) 
(11 to 
14) 
 
 
0 
5 
2 
14 
 
 
(11) 
(57) 
(43) 
(13 to 
15) 
Abnormality on aEEG at trial entry, n (%): 
Moderate 
Severe 
 
6 
26 
 
(19) 
(81) 
 
6 
24 
 
(20) 
(80) 
 
12 
50 
 
(19) 
(81) 
 
1 
6 
 
(14) 
(86) 
Age cooling commenced (hours), n (%): 
0 to 4 hours 
4 to 6 hours 
Median (IQR) 
Unknown 
 
27 
3 
0.2 
2 
 
(90) 
(10) 
(0.1 to 2.8) 
 
25 
3 
0.4 
2 
 
(89) 
(11) 
(0.1 to 0.9) 
 
52 
6 
0.4 
4 
 
(90) 
(10) 
(0.1 to 
1.8) 
 
7 
0 
0.2 
0 
 
(100) 
(0) 
(0.1 to 
3.0) 
Head circumference at admission to 
neonatal unit (cm): 
Mean [SD] 
Unknown 
 
 
34.3 
11 
 
 
[1.4] 
 
 
34.6 
6 
 
 
[1.6] 
 
 
34.5 
17 
 
 
[1.5] 
 
 
34.4 
2 
 
 
[1.2] 
 
Table 2 Neurodevelopmental outcomes at age 2-3 years 
Developmental score* 
 Xenon plus hypothermia Hypothermia only Difference in 
Medians  
(95% CI) 
P value 
 N=32 N=30   
Cognitive, Median 
(IQR) 
90 (67.5 to 100) 90 (75 to 95) 0 (0 to 5) P=0.826 
Language, Median 
(IQR) 
92.5 (62 to 104.50) 91 (77 to 100) 1.5 (0 to 3) P=0.989 
 
Motor, Median 
(IQR) 
97 (64 to 103) 94 (67 to 100) 3 (0 to 8) P=0.874 
 
Optimality score 
 Xenon plus hypothermia Hypothermia only   
 N=23 N=22   
Median (IQR) 71 (66 to 73) 70.5 (60.50 to 76) 0.5 (2 to 0) P=0.794 
 
GMFCS 
 Xenon plus hypothermia Hypothermia only  
 N=32 N=30  
Level 1-2, n (%) 2 (6.25) 5 (16.67)  
Level 3-5, n (%) 6 (18.75) 3 (9.38) RR (95% CI)1 1.875 (0.514 
to 6.834) 
 
MACS 
 Xenon plus hypothermia Hypothermia only  
 N=32 N=30  
Level 1-2, n (%) 2 (6.25) 6 (20)  
Level 3-5, n (%) 6 (18.75) 2 (6.67) 
 
RR (95% CI)2 2.813 (0.615 
to 12.871) 
 
Disability 
 Xenon plus hypothermia Hypothermia only  
 N=32 N=30  
Mild, n (%) 3 (9.38) 5 (16.67)  
Moderate, n (%) 2 (6.25) 3 (9.38) RR (95% CI) 3 1.071 (0.443 
to 2.593) Severe, n (%) 6 (18.75) 4 (13.33) 
*One child in each allocation group was tested by WPPSI-III. Their scores were: Verbal IQ 101 and 84; 
Performance IQ 84 and 100; Full scale IQ 90 and 89. All other participants were tested using the Bayley-III 
Scales. 
1Relative risk for GMFCS level 3-5 
2Relative risk for MACS level 3-5 
3Relative risk for moderate/severe disability 
 
Table 3. Regression coefficients from the association of Lac/NAA ratios and FA with developmental scores  
 
 Coefficient (95%CI) r2 P value 
Cognitive 
Log Lac/NAA Slope -13.345  
(-17.381 to -9.308) 
0.444 <0.001 
Intercept 61.927 (53.636 to 70.216) 
Fractional Anisotropy Slope 195.728 (105.935 to   285.521) 0.263 <0.001 
Intercept 7.432 (-29.420 to 44.286) 
Language 
Log Lac/NAA Slope -15.365  
(-20.403 to -10.328) 
0.400 <0.001 
Intercept 60.582 (50.238 to 70.926) 
Fractional Anisotropy Slope   259.991 (158.404 to 361.578) 0.332 <0.001 
Intercept -16.291 (-57.976 to 25.393) 
Motor 
Log Lac/NAA Slope -18.305  
(-22.946 to -13.664) 
0.548 <0.001 
Intercept 54.791 (45.608 to 63.976) 
Fractional Anisotropy Slope 262.600 (167.067 to    358.133) 0.374 <0.001 
Intercept -19.764 (-59.034 to 19.506) 
 
Table 4. Biomarker values in infants with and without disability 
 
 
 
*Difference between the moderate/severe disability and deaths group and the normal outcome/minor disability group  
a This is sqrt(exp(var)-1) where var is the variance on the log scale 
b This is the ratio of the standard deviation to the arithmetic mean in the original untransformed data 
1 Two group t test of means of Lac/NAA on the log scale, in normal outcome/mild disability and moderate/severe disability/deaths groups 
2 Wilcoxon rank-sum test, in normal outcome/mild disability and moderate/severe disability/deaths groups 
3 Two group t test of means of FA, in normal outcome/mild disability and moderate/severe disability/deaths groups  
 
 
 Normal outcome/minor 
disability 
Moderate/severe 
disability 
Moderate/severe 
disability 
 and deaths 
Difference 
(95% CI)* 
 
P value 
Lac/NAA N=45 N=12 N=26   
 Arithmetic mean (SD) 0.136 (0.067) 
 
0.816 (1.13) 
 
1.287 (1.500) 
 
1.151 (1.59 to 0.707) P<0.001
1 
 Coefficient of 
variationa 
0.654 1.351 1.462   
 Median [IQR] 0.142 [0.080 to 0.185] 0.600 [0.237 to 0.774] 0.770 [0.392 to 1.575] 0.628 (-0.370 to 
4.684) 
P=0.005
2 
     
Fractional Anisotropy N=44 N=12 N=22   
 Arithmetic mean (SD) 0.422 (0.034) 0.354 (0.051) 0.368 (0.055) -0.055 (-0.033 to -
0.077) 
P<0.001
3  
 Coefficient of 
variationb 
0.080 0.144 0.149   
 Median [IQR] 0.420 [0.403 to 0.445] 0.358 [0.310 to 0.402] 0.382 [0.328 to 0.401] -0.038 (-0.09 to -
0.053) 
P<0.001
2 
Table 5: Predictive accuracy of early cerebral biomarkers for moderate/severe disability or death at 2-3 years 
 
Participating survivors at 2-3 years 
 Correctly 
classified 
(%), 
[cutpoint] 
AUCa 
(95% CI) 
Sensitivity 
(%) 
Specificity 
(%) 
LRb+ LRb- P value 
Lac/NAA 
(N=57) 
91.53 
[>=0.308] 
0.752 
(0.548 to 
0.954) 
64.29 100.00 infinite 
 
0.357 0.001 
FA 
(N=56) 
87.50  
[<=0.363] 
0.877 
(0.773 to 
0.982) 
66.67 93.18 9.777 0.357 0.001 
Lac/NAA + 
FA (N=52) 
94.20 
[>=0.591] 
0.914 
(0.807 to 
1.000) 
70.00 100.00 infinite 0.300 0.002 
 
Participants including deaths  
Lac/NAA 
(N=71) 
95.65 
[>=0.308] 
0.938 
(0.866 to 
1.000) 
88.46 100.00 infinite 0.153 <0.001 
FA 
(N=66) 
78.79 
[<=0.403] 
0.818 
(0.703 to 
0.934) 
81.82 77.27 3.600 0.253 <0.001 
Lac/NAA + 
FA (N=63) 
93.65 
[>=0.611] 
0.955 
(0.903 to     
1.000) 
80.95 95.24 17.006 0.200 <0.001 
 
aAUC: area under the curve 
bLR: Likelihood ratio  
 
Reference List 
 
 
 
 
 
 1.  Liu X, Dingley J, Scull-Brown E, Thoresen M. Adding 5 h delayed xenon to delayed hypothermia 
treatment improves long-term function in neonatal rats surviving to adulthood. Pediatr.Res. 
2015;77(6):779-83. 
 2.  Ma D, Hossain M, Chow A, Arshad M, Battson RM, Sanders RD et al. Xenon and hypothermia combine 
to provide neuroprotection from neonatal asphyxia. Ann.Neurol. 2005;58(2):182-93. 
 3.  Laitio R, Hynninen M, Arola O, Virtanen S, Parkkola R, Saunavaara J et al. Effect of Inhaled Xenon on 
Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: A Randomized 
Clinical Trial. JAMA 2016;315(11):1120-8. 
 4.  Faulkner S, Bainbridge A, Kato T, Chandrasekaran M, Kapetanakis AB, Hristova M et al. Xenon 
augmented hypothermia reduces early lactate/N-acetylaspartate and cell death in perinatal asphyxia. 
Ann.Neurol. 2011;70(1):133-50. 
 5.  Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks NP, Dickinson R. Neuroprotection against 
traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-D-aspartate 
receptor glycine site. Anesthesiology 2013;119(5):1137-48. 
 6.  Ma D, Williamson P, Januszewski A, Nogaro MC, Hossain M, Ong LP et al. Xenon mitigates isoflurane-
induced neuronal apoptosis in the developing rodent brain. Anesthesiology 2007;106(4):746-53. 
 7.  Azzopardi D, Robertson NJ, Bainbridge A, Cady E, Charles-Edwards G, Deierl A et al. Moderate 
hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth 
asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 
2016;15(2):145-53. 
 8.  Thayyil S, Chandrasekaran M, Taylor A, Bainbridge A, Cady EB, Chong WK et al. Cerebral magnetic 
resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics 2010;125(2):e382-e395. 
 9.  Tusor N, Wusthoff C, Smee N, Merchant N, Arichi T, Allsop JM et al. Prediction of neurodevelopmental 
outcome after hypoxic-ischemic encephalopathy treated with hypothermia by diffusion tensor imaging 
analyzed using tract-based spatial statistics. Pediatr.Res. 2012;72(1):63-9. 
 10.  Lally PJ, Montaldo P, Oliveira V, Soe A, Swamy R, Bassett P et al. Magnetic resonance spectroscopy 
assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective 
multicentre cohort study. Lancet Neurol. 2019;18(1):35-45. 
 11.  Mitra S, Kendall GS, Bainbridge A, Sokolska M, Dinan M, Uria-Avellanal C et al. Proton magnetic 
resonance spectroscopy lactate/N-acetylaspartate within 2 weeks of birth accurately predicts 2-year motor, 
cognitive and language outcomes in neonatal encephalopathy after therapeutic hypothermia. 
Arch.Dis.Child Fetal Neonatal Ed 2019;104(4):F424-F432. 
 12.  Berger HR, Brekke E, Wideroe M, Morken TS. Neuroprotective Treatments after Perinatal Hypoxic-
Ischemic Brain Injury Evaluated with Magnetic Resonance Spectroscopy. Dev.Neurosci. 2017;39(1-4):36-
48. 
 13.  Groenendaal F, de Vries LS. Fifty years of brain imaging in neonatal encephalopathy following perinatal 
asphyxia. Pediatr.Res. 2017;81(1-2):150-5. 
 14.  Robertson NJ, Thayyil S, Cady EB, Raivich G. Magnetic resonance spectroscopy biomarkers in term 
perinatal asphyxial encephalopathy: from neuropathological correlates to future clinical applications. 
Curr.Pediatr.Rev. 2014;10(1):37-47. 
 15.  Bayley, N. Bayley scales of infant and toddler development: administration manual.  2006. San Antonio, 
TX, USA, Harcourt Assessment.  
 
 16.  Wechsler, D. Wechsler Preschool & Primary Scale of Intelligence - Third UK Edition (WPPSI-III UK).  
2003. London, UK, Pearson Corporation.  
 
 17.  Haataja L, Mercuri E, Guzzetta A, Rutherford M, Counsell S, Flavia FM et al. Neurologic examination in 
infants with hypoxic-ischemic encephalopathy at age 9 to 14 months: use of optimality scores and 
correlation with magnetic resonance imaging findings. J.Pediatr. 2001;138(3):332-7. 
 18.  Palisano RJ, Rosenbaum P, Bartlett D, Livingston MH. Content validity of the expanded and revised 
Gross Motor Function Classification System. Dev.Med.Child Neurol. 2008;50(10):744-50. 
 19.  Amess PN, Penrice J, Cady EB, Lorek A, Wylezinska M, Cooper CE et al. Mild hypothermia after severe 
transient hypoxia-ischemia reduces the delayed rise in cerebral lactate in the newborn piglet. Pediatr.Res. 
1997;41(6):803-8. 
 20.  Robertson NJ, Faulkner S, Fleiss B, Bainbridge A, Andorka C, Price D et al. Melatonin augments 
hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013;136(Pt 1):90-105. 
 21.  Broad KD, Fierens I, Fleiss B, Rocha-Ferreira E, Ezzati M, Hassell J et al. Inhaled 45-50% argon 
augments hypothermic brain protection in a piglet model of perinatal asphyxia. Neurobiol.Dis. 
2016;87:29-38. 
 22.  Rutherford M, Ramenghi LA, Edwards AD, Brocklehurst P, Halliday H, Levene M et al. Assessment of 
brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a 
nested substudy of a randomised controlled trial. Lancet Neurol. 2010;9(1):39-45. 
 23.  Sabir H, Osredkar D, Maes E, Wood T, Thoresen M. Xenon Combined with Therapeutic Hypothermia Is 
Not Neuroprotective after Severe Hypoxia-Ischemia in Neonatal Rats. PLoS.One. 2016;11(6):e0156759. 
 24.  Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic 
ischaemic encephalopathy. Cochrane.Database.Syst.Rev. 2013(1):CD003311. 
 
 
